The second batch of purchasing with volume was implemented, and drug companies took the initiative to reduce prices

[industry trends of pharmaceutical network] at the end of 2019, Jiangsu pharmaceutical procurement platform issued a notice that according to the application of the enterprise, it plans to adjust the price of some drugs The adjustment covers 16 commonly used clinical drugs, such as captopril of Sinopharm group, paclitaxel albumin of Hengrui medicine, and tolfatipu of Zhengda Tianqing, with a high drop of more than 70% According to the requirements of Jiangsu pharmaceutical production platform, the price adjustment will be implemented from December 30, 2019 I learned that in fact, in addition to Jiangsu, Zhejiang, Gansu, Guizhou and other provinces also announced the news of active application for price reduction of commonly used drugs at the end of last year, and in addition to the active price reduction of local pharmaceutical enterprises, multinational pharmaceutical enterprises such as GSK also participated in the trend of price reduction From the perspective of drugs with active price reduction, it mainly includes the drugs failed to win the bid in the 4 + 7 volume purchase pilot and expansion, as well as the varieties not involved in the volume purchase when the price is reduced to strive for the margin market At present, the second batch of drugs with volume procurement has been started, involving 33 new varieties, and will be opened on January 17 this year The industry believes that the price reduction trend reflected in the volume purchase is certain from the start of the centralized purchase of drugs in December 2018 to the expansion of the volume purchase in September 2019, as well as the second batch of centralized purchase of drugs Therefore, in the case of decreasing profit margin of generic drugs and some original research drugs, both winning enterprises and unsuccessful enterprises, especially multinational pharmaceutical enterprises and local leading enterprises, should actively adjust the price strategy and strive for more market share for their products The author notes that under the continuous influence of the new medical reform policy, the "ruthless force" of price reduction of multinational pharmaceutical enterprises is no less than that of local pharmaceutical enterprises Among the results of centralized recruitment and selection of "4 + 7" pilot areas initially announced, almost all multinational pharmaceutical enterprises were "occupied", only AstraZeneca and Bristol Myers Shigui were shortlisted With the landing of volume purchase, the trend of price reduction of original research drugs has been very obvious Multinational pharmaceutical companies began to actively layout the domestic market through active price reduction For example, on April 2, Liaoning Pharmaceutical centralized purchase network released a notice on price adjustment of kagliflon and engelieflon tablets Xi'an Janssen's caglejing tablets (yike'an) and Shanghai bolingyingehan pharmaceutical's engelejing tablets (Ou Tangjing) actively applied for price reduction in Liaoning On April 3, Heilongjiang medicine centralized purchase network issued a notice on price adjustment of some drugs The price reduction involves Novo Nordisk's novo Heda (degu insulin injection), Sanofi's Dalong (amiodarone hydrochloride injection) and Novartis' Gleevec (imatinib mesylate tablets) In the national health insurance catalog negotiation in 2019, 41 of the 52 new Western medicines won the bid came from multinational pharmaceutical giants such as Novartis and Pfizer, accounting for nearly 80% Among them, Novartis ranked first in seven seats, while Roche followed with five There is no doubt that these multinational pharmaceutical companies entering the medical insurance will offer low prices For example, adamumumab injection of albove has applied for price reduction in Jiangxi, Beijing, Shaanxi and other places since 2019 The price of 40mg / 0.8ml/tablet has been adjusted from 7608.38 yuan to 3160 yuan, with a decrease of 60% However, in this round of negotiations, xiumeile once again cut 1290 yuan (40mg / 0.4ml) by a large margin, down 59.2% In addition to price reduction, many multinational pharmaceutical companies have begun to adjust their strategic structure to adapt to the development of the domestic market For example, the head of Sanofi said publicly that the company will continue to develop its existing business, accelerate the listing of new products, increase investment in the Chinese market, and promote digital innovation to improve patient benefit / treatment effect Meanwhile, Sanofi plans to introduce more than 20 innovative drugs and vaccines by 2025 Novartis also issued a statement saying that Novartis decided to focus the operation of Shanghai R & D center on expanding the scale and field of early clinical development and later clinical trials, so as to accelerate the development of new drugs It is expected that the company will submit 50 new drug applications in China during 2019-2023 In the long run, the development momentum of multinational pharmaceutical enterprises in the Chinese market is still strong In the future, the competition between local pharmaceutical enterprises and multinational pharmaceutical enterprises will be more intense and the cooperation will be closer.